Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于公司预计2023年度日常关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution regarding the expected daily related-party transactions for the fiscal year 2023 of Shanghai Medicilon Inc. It includes descriptions of the approval procedures by the board and supervisory committee, independent directors' opinions, transaction amounts, related parties, and compliance with relevant laws and regulations. The document is not a financial report itself but a regulatory compliance and verification statement related to related-party transactions. It does not contain financial statements or earnings data but focuses on governance and regulatory compliance aspects of related-party transactions. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification report rather than a financial report or announcement of voting results or management changes.
2023-04-25 Chinese
美迪西：2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers the period January to March 2023. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is over 12,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-25 Chinese
美迪西：股东大会议事规则（2023年修订）
Governance Information Classification · 100% confidence The document is titled "股东大会议事规则" which translates to "Shareholders' Meeting Rules" or "Rules of Procedure for the Shareholders' General Meeting". It extensively details the procedures, powers, and regulations governing the company's shareholders' meetings, including the rights and responsibilities of shareholders, the convening and conduct of meetings, voting procedures, and related governance matters. There is no indication that this is an announcement of a meeting, a voting result, or a report of financial results. Instead, it is a governance document outlining internal rules and procedures related to the shareholders' meetings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length and content confirm it is a full governance report, not a brief announcement or notice.
2023-04-25 Chinese
美迪西：第三届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the 3rd Board of Directors of Shanghai Medicilon Inc. It includes approvals of various reports and proposals such as the 2022 Annual Board Work Report, 2022 General Manager Work Report, 2022 Independent Directors' Report, 2022 Audit Committee Report, 2022 Financial Statements, 2022 Profit Distribution Plan, 2022 Annual Report, 2023 Q1 Report, 2022 Internal Control Evaluation Report, and others. The document repeatedly states that these reports and proposals will be submitted to the shareholders' meeting for approval and provides links to the full reports on the Shanghai Stock Exchange website. The document itself is a formal board meeting resolution announcement, not the reports themselves. It also includes items like appointment of auditors, capital changes, governance amendments, and social responsibility report approvals. The document length is 6713 characters, which is relatively short for containing full reports. The presence of phrases like "具体内容详见公司于同日刊登在上海证券交易所网站" (detailed content is published on the SSE website) indicates this document is an announcement of board meeting resolutions and approvals, not the full reports. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting decisions and management reports approvals.
2023-04-25 Chinese
美迪西：独立董事关于第三届董事会第十五次会议相关事项的事前认可意见
Regulatory Filings
2023-04-25 Chinese
美迪西：2022年度独立董事述职报告
Regulatory Filings
2023-04-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.